加载中
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
前收盘价
US$19.60
−US$0.34 · -1.71%
盘后
US$19.60
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
日内区间
当前US$19.60
52周区间
当前US$19.60
盘中时间采用ET。市场数据可能有所延迟。
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
日内区间
当前US$19.60
52周区间
当前US$19.60
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.03亿 USD | 8007.7万 USD | 6251.8万 USD | 4300.8万 USD | 2063.6万 USD |
| 销售、一般及管理费用 | 2983.4万 USD | 2410万 USD | 1742.7万 USD | 1591.9万 USD | 565.2万 USD |
| 营业费用 | 1.33亿 USD | 1.04亿 USD | 7994.5万 USD | 5892.7万 USD | 2628.8万 USD |
| 利息收入 | 1281.5万 USD | 1769.6万 USD | 1081.1万 USD | 365.2万 USD | 1.3万 USD |
| 折旧和摊销 | 54.6万 USD | 51.9万 USD | 35.7万 USD | 29.6万 USD | 14万 USD |
| 营业利润 | −1.33亿 USD | −1.04亿 USD | −7994.5万 USD | −5892.7万 USD | −2628.8万 USD |
| 净利润 | −1.2亿 USD | −8648.1万 USD | −6913.4万 USD | −5532.5万 USD | −2629.4万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$45.17
上涨空间 130.46%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2842.09万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2267.15万0.23%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1923.92万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF862.97万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB817.31万0.08%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO674.49万0.05%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO529.18万0.03%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA454.65万0.02%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
